S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
Log in

NASDAQ:VCYT - Veracyte Stock Price, Forecast & News

$29.18
-0.81 (-2.70 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$29.13
Now: $29.18
$30.61
50-Day Range
$20.99
MA: $25.14
$29.95
52-Week Range
$10.73
Now: $29.18
$31.18
Volume526,303 shs
Average Volume644,302 shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$92.01 million
Book Value$1.97 per share

Profitability

Net Income$-23,000,000.00

Miscellaneous

Employees270
Market Cap$1.43 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.


Veracyte (NASDAQ:VCYT) Frequently Asked Questions

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) posted its quarterly earnings results on Tuesday, October, 22nd. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. The biotechnology company earned $30.97 million during the quarter, compared to analysts' expectations of $30.41 million. Veracyte had a negative net margin of 7.08% and a negative return on equity of 5.33%. View Veracyte's Earnings History.

When is Veracyte's next earnings date?

Veracyte is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Veracyte.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte issued an update on its FY 2019 earnings guidance on Tuesday, October, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $119-122 million, compared to the consensus revenue estimate of $120.14 million.

What price target have analysts set for VCYT?

3 brokerages have issued 1 year price targets for Veracyte's shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Veracyte's stock price to reach $28.67 in the next twelve months. This suggests that the stock has a possible downside of 1.8%. View Analyst Price Targets for Veracyte.

What is the consensus analysts' recommendation for Veracyte?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.

Has Veracyte been receiving favorable news coverage?

News stories about VCYT stock have been trending somewhat negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Veracyte earned a news impact score of -1.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Veracyte.

Are investors shorting Veracyte?

Veracyte saw a drop in short interest in November. As of November 15th, there was short interest totalling 2,640,000 shares, a drop of 35.5% from the October 31st total of 4,090,000 shares. Based on an average daily volume of 612,600 shares, the days-to-cover ratio is currently 4.3 days. Approximately 5.8% of the shares of the company are short sold. View Veracyte's Current Options Chain.

Who are some of Veracyte's key competitors?

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), Advanced Micro Devices (AMD), InVitae (NVTA), Netflix (NFLX), AbbVie (ABBV), Chipotle Mexican Grill (CMG) and Exelixis (EXEL).

Who are Veracyte's key executives?

Veracyte's management team includes the folowing people:
  • Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
  • Mr. Christopher M. Hall, Pres & COO (Age 50)
  • Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
  • Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
  • Mr. Ashish Kheterpal, Chief Information Officer

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (5.66%), Sumitomo Mitsui Trust Holdings Inc. (5.66%), State Street Corp (4.33%), Versant Venture Management LLC (2.49%), Pictet Asset Management Ltd. (1.84%) and Millennium Management LLC (0.74%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Institutional Ownership Trends for Veracyte.

Which major investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Versant Venture Management LLC, Russell Investments Group Ltd., Calamos Advisors LLC, Castleark Management LLC, Essex Investment Management Co. LLC, Perkins Capital Management Inc. and Barclays PLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Insider Buying and Selling for Veracyte.

Which major investors are buying Veracyte stock?

VCYT stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Pictet Asset Management Ltd., Nikko Asset Management Americas Inc., State Street Corp, KAMES CAPITAL plc, State of New Jersey Common Pension Fund D, Railway Pension Investments Ltd and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Veracyte.

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $29.18.

How big of a company is Veracyte?

Veracyte has a market capitalization of $1.43 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.

What is Veracyte's official website?

The official website for Veracyte is http://www.veracyte.com/.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]


MarketBeat Community Rating for Veracyte (NASDAQ VCYT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  560
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel